JP Morgan Chase
AKRO

JP Morgan Chase’s Akero Therapeutics AKRO Stock Holding History

JP Morgan Chase’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,000
Closed -$884K – 7316
2024
Q1 		$884K Sell
35,000
-7,100
-17% -$171K ﹤0.01% 4437
2023
Q4 		$983K Sell
42,100
-209,800
-83% -$4.14M ﹤0.01% 4341
2023
Q3 		$12.7M Buy
251,900
+37,900
+18% +$1.76M ﹤0.01% 2042
2023
Q2 		$9.99M Buy
214,000
+199,000
+1,327% +$9.12M ﹤0.01% 2289
2023
Q1 		$574K Hold
15,000
– – ﹤0.01% 4409
2022
Q4 		$822K Buy
+15,000
New +$643K ﹤0.01% 4185

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's AKRO Position: Q4 2025 in Review

JP Morgan Chase sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 288,970 shares — an estimated $13.7M sold.

JP Morgan Chase first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $36.1M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • JP Morgan Chase reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 288,970 Akero Therapeutics shares in Q4 2025, an estimated $13.7M.
  • JP Morgan Chase first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
  • JP Morgan Chase's Akero Therapeutics position peaked at $36.1M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.